Jeanie Magdalena Gatewood’s Post

In-house molecular biomarker results within 3 hours 🔬. THINK IDYLLA™ Because time matters Biocartis offers tests supporting melanoma, colorectal, lung, breast, thyroid and liver cancer. Learn more about the clinical utility of Idylla on the Abacus dx website → https://lnkd.in/gCbxD3CP #abacusdx #biocartis #idylla

Results from an early phase clinical trial suggest that the combination of enfortumab vedotin and cabozantinib is “safe and tolerable” for patients with metastatic urothelial carcinoma. The trial, led by a team from Winship Cancer Institute of Emory University, is the first to examine combining an antibody-drug conjugate and tyrosine kinase inhibitor in this specific disease. Learn more: https://lnkd.in/g2fAfkDu

At #ESMO24, the results of an ancillary study of STAMPEDE were presented, evaluating the Decipher Score for prediction of survival benefit when combining docetaxel with hormone therapy in metastatic hormone sensitive #ProstateCancer patients. High Decipher Score identified patients were more likely to benefit from treatment intensification with docetaxel, independently of tumor volume. Decipher is the first molecular classifier to show a statistically significant interaction with docetaxel in randomized metastatic prostate cancer patients. Learn more here: https://lnkd.in/g-bxADDF

At #ESMO24, Late-Breaking Abstracts provide evidence for the efficacy benefits of radioisotopes, radium (Ra)-223 and 177Lu-PNT2002, in metastatic castration-resistant prostate cancer (#mCRPC). In the PEACE-3 trial, radiological PFS and OS (interim analysis) were longer with Ra-223 plus enzalutamide versus enzalutamide alone in patients with mCRPC and bone metastases. Initial radiological PFS results appeared encouraging for 177Lu-PNT2002 in PSMA-positive mCRPC after progression. The final results are eagerly anticipated, according to Karim Fizazi, who provides insights on these findings on the #ESMODailyReporter 👉https://ow.ly/Hkbq50TnIQz

In this edition, we are sharing an update on the: 💡 Selective RET Inhibitor Selpercatinib Demonstrated Favorable Clinical Outcome over Cabozantinib or Vandetanib in RET-mutant Medullary Thyroid Cancer. 💡 DESTINY-PanTumor02: The ADC trastuzumab deruxtecan (T-DXd) showed activity in HER2-expressing solid tumors. 💡 Detection Discrepancies in HER2 Amplification: Implications for Therapeutic Strategies - Insights from the MOUNTAINEER Study Presented at the 2023 #ASCO and #ESMO Annual Meetings. Find out more on our #ACTGenomics Blog: https://lnkd.in/g-WU-Upi

📋 Results from an early phase clinical trial suggest that the combination of enfortumab vedotin and cabozantinib is “safe and tolerable” for patients with metastatic urothelial carcinoma. 📰 The trial, led by a team from Winship Cancer Institute of Emory University, is the first to examine combining an antibody-drug conjugate and tyrosine kinase inhibitor in this specific disease. ➡ Learn more: https://lnkd.in/g2fAfkDu

[ON-DEMAND WEBINAR] Learn how to leverage microplate reader technology to streamline and enhance your organoid-based cancer research. This NEW webinar, presented by Krystal Courtney Belmonte, Ph.D. and Angeline Lim, Ph.D. showcases innovative techniques for identifying and assessing drug candidates using patient-derived colorectal #cancer #organoids. https://lnkd.in/e9p2Rayd

New Imaging Technique Accurately Detects Aggressive Kidney Cancer A study led by UCLA Health introduces a non-invasive imaging technique that uses the monoclonal antibody 89Zr-TLX250 to target the CA9 protein, commonly present in clear-cell renal cell carcinoma. This new method, validated through a phase 3 trial, shows high accuracy in detecting aggressive kidney cancer, with 85.5% sensitivity and 87.0% specificity. The technique minimizes unnecessary surgeries and improves treatment outcomes, offering a significant advance in kidney cancer diagnostics. For more details, visit the UCLA Health article:https://lnkd.in/dht4pFRj #healthcareinnovation #bme #medicalimaging

Learn how to leverage microplate reader technology to streamline and enhance your organoid-based cancer research. This NEW #webinar, presented by Krystal Courtney Belmonte, Ph.D. and Angeline Lim, Ph.D. showcases innovative techniques for identifying and assessing drug candidates using patient-derived colorectal #cancer #organoids. https://lnkd.in/e9p2Rayd

Introducing the 3rd Episode of ProNews' 4th Edition: "Proton therapy in Hepatocellular CA" In this episode, we dive into the most advanced treatment of hepatocellular carcinoma (liver cancer). Liver cancer, often associated with chronic liver disease, can benefit significantly from advanced proton therapy. Click here to watch video: https://lnkd.in/dsyn74tA Dr Ashu Abhishek Arjunan Manikandan #APCC #ProNews #ProtonTherapy #LiverCancer